Shares of Shield Therapeutics plc (LON:STX – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 8.40 ($0.11) and last traded at GBX 7.50 ($0.10), with a volume of 4933893 shares. The stock had previously closed at GBX 8.25 ($0.11).
Shield Therapeutics Stock Performance
The stock has a fifty day simple moving average of GBX 4.13 and a 200-day simple moving average of GBX 3.28. The stock has a market cap of £74.01 million, a P/E ratio of -1.93 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
See Also
- Five stocks we like better than Shield Therapeutics
- Business Services Stocks Investing
- Tesla Just Had Its Best Day in 2 Months—Here’s What It Means
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- Retail Roundup: Key Winners and Losers After Q2 Earnings
- Profitably Trade Stocks at 52-Week Highs
- Big Analyst Revisions Could Be Ahead for SoFi Stock
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
